RTTNews BiotechDoubao · 实盘不做把握 8/10不做原因:已被定价
北京时间·🕒 发布 15:42:28·⟳ 抓取 15:45:13 +2m45s·⚡ 决策 10-26 15:47:19 +2m06s·1.0 天前
GSK AZUR-1（Jemperli 单药治疗 MSI-H/dMMR 局晚直肠癌）76% 完全缓解数据及 Mo-Rez 卵巢癌 I 期更新数据公布
本条为 RTTNews 对 GSK 10 月 24 日新闻稿的滞后转述（晚约 2 天）；AZUR-1 数据支撑的 Jemperli 直肠癌适应症 FDA 批准已在 10 月 19 日前后落地，核心利好已兑现；Mo-Rez 仅为 I 期更新、III 期尚早。对约 1017 亿美元市值的 GSK 而言，该窄适应症与早期资产均无可交易短线增量，且股价近 5 日已上涨约 9.4% 完成定价，盘前/隔夜无正向反应（约 -0.3%~-0.9%）。
📄 原文RTTNews Biotech↗ 原文
GSK: AZUR-1 Data Demonstrates Potential Of Jemperli
GSK plc (GSK,GSK.L) announced positive interim results from the phase II AZUR-1 trial evaluating Jemperli, or dostarlim…
不做 GSK plc（GSK.US）
旧闻重报且核心利好已兑现：新闻稿 10-24 首发、FDA 批准 10-19 已落地，数据为探索性更新；约 1017 亿美元市值超大盘药企，窄适应症与 I 期资产无可交易增量；近 5 日已涨约 9.4%，隔夜/盘前不涨反跌，无预期差与短线 edge。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
正面但陈旧：数据新闻稿 10-24 已发、适应症批准 10-19 已落地，超大盘药企 GSK 的临床更新相对千亿美元市值无实质增量，近 5 日已涨约 9%，无预期差，不做。
消息传播链
- RTTNews 转述 GSK AZUR-1 与 BEHOLD-1 数据，比公司新闻稿晚约 2 天，无新增事实市场反应:GSK 美股隔夜约 50.58 美元、-0.33%，盘前相对前收约 -0.8%，无正向跳空
- GSK 官方新闻稿披露 AZUR-1 76% CR 及 Mo-Rez 卵巢癌更新数据，为本催化真实首发
关键理由
- AZUR-1 76% 完全缓解、超 2 年无复发强化 Jemperli 在 dMMR/MSI-H 直肠癌（约占直肠癌 5%-10%）免放化疗单药逻辑
- Mo-Rez 在铂耐药卵巢癌 62% ORR、11.1 个月 PFS 为后续 III 期提供依据，但属早期探索数据
主要风险
- 76% CR 为探索性分析、样本量有限，且 Jemperli 该适应症已获批，数据本身不构成新的监管或销售里程碑
- Mo-Rez 距 III 期读出与商业化仍远，短期不影响 GSK 盈利预期
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-19 · 影响 invalidates
适应症批准与新闻稿均早于本条转述，GSK 近 5 日已涨约 9.4%，盘前/隔夜无正向反应，利好已消化
检索:GSK Jemperli rectal cancer FDA approval already announced October 2026 原文 ↗
先例如何影响了这次决策
对本次决策的影响:不改变 AVOID 结论
方向:未运行先例统计：结论为 AVOID（旧闻重报+超大盘软催化），方向与幅度无需先例校准
涨幅量级:无可用于校准的对齐先例；但 GSK 隔夜与盘前已无正向反应，本身确认无剩余 edge
形态:不适用
工具执行结果 · 成功 2 · 降级 1 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 215 ms
{"result": "search_processed_events:agent query=`azur-1 76% complete response locally advanced rectal cancer msi-h | gsk jemperli dostarlimab azur-1 phase ii rectal cancer complete response | gsk mocertatug rezetecan mo-rez behol`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 71.4/72 小时、1701 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 - web_search 成功 doubao_search · 1,543 ms
豆包搜索结果（原始查询:GSK AZUR-1 Jemperli dostarlimab rectal cancer 76% complete response BEHOLD-1 mocertatug rezetecan；API SearchType:web） - stock_quote 降级 stock_tools HTTP · 924 ms
{
原文全文
展开原文 · 1,595 字
GSK plc (GSK,GSK.L) announced positive interim results from the phase II AZUR-1 trial evaluating Jemperli, or dostarlimab monotherapy as a standalone treatment approach in adults with stage II and III microsatellite instability-high/mismatch repair deficient locally advanced rectal cancer. In an exploratory analysis, 76% of evaluable patients achieved a complete response to dostarlimab alone. No disease recurrences have been reported among responders to date after a median follow-up of more than two years.
Separately, GSK plc announced updated data from the global phase I BEHOLD-1 trial for mocertatug rezetecan, or Mo-Rez in platinum-resistant ovarian cancer. Results showed clinically meaningful and durable responses at >13 months follow-up, building on initial data in platinum-resistant ovarian cancer announced earlier in the current year. Mo-Rez achieved a confirmed objective response rate of 62%, with a median duration of response of 12.2 months at the selected phase III dose of 5.8 mg/kg. Median progression-free survival was 11.1 months.
At last close on LSE, GSK shares were trading at 1,893.28 pence.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
October 16, 2026 16:06 ET Monthly consumer price inflation data and retail sales figures were the main news from the U.S. economy this week. In Europe, monthly GDP figures from the U.K. gained attention. External trade data from China was in focus in Asia. Elsewhere, the International Monetary Fund released its latest projections for the global economy.
Separately, GSK plc announced updated data from the global phase I BEHOLD-1 trial for mocertatug rezetecan, or Mo-Rez in platinum-resistant ovarian cancer. Results showed clinically meaningful and durable responses at >13 months follow-up, building on initial data in platinum-resistant ovarian cancer announced earlier in the current year. Mo-Rez achieved a confirmed objective response rate of 62%, with a median duration of response of 12.2 months at the selected phase III dose of 5.8 mg/kg. Median progression-free survival was 11.1 months.
At last close on LSE, GSK shares were trading at 1,893.28 pence.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
October 16, 2026 16:06 ET Monthly consumer price inflation data and retail sales figures were the main news from the U.S. economy this week. In Europe, monthly GDP figures from the U.K. gained attention. External trade data from China was in focus in Asia. Elsewhere, the International Monetary Fund released its latest projections for the global economy.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
841b4a8060· 2026-10-26 15:47 · doubao / doubao-seed-evolving-latest-version · 策略包b7b4acf827b8当前